Hims & Hers Health Inc. Aktie News

Hims stock is nearing a trendline entry after earnings gave shares a boost on May 6. The telehealth provider leads the IBD 50.

There's a well-known saying in the investing world, which advises investors to “sell in May and go away.

Hims & Hers Health's rapid revenue and subscriber growth, plus improving cash generation, highlight strong business momentum and brand strength. Gross margins have declined due to lower-margin obesity products, but SG&A as a percentage of revenue is improving, supporting better operating leverage. The recent Novo Nordisk collaboration and capital raise position Hims for expansion, though relian...

Hims & Hers stock price has surged and is nearing its all-time high as investors bet that its strong momentum will continue in the coming years. HIMS shares surged by almost 16% on Tuesday, reaching its highest level since February.

Stay on our website for longer than five minutes and you're bound to find references to Schaeffer's Volatility Scorecard (SVS). The internal metric is a goldmine for options traders, helping identify opportunities using a scored rating of volatility expectations in the last year. But there's more to SVS than meets the eye; the hypothetical straddle trades that are foundational to SVS can be tak...

U.S. equity markets have faced significant volatility in 2025 as ongoing trade disputes, inflation uncertainty, and geopolitical tensions continue to weigh on investor sentiment. Growth-oriented companies, in particular, have seen heightened pressure, with many high-multiple stocks experiencing sharp drawdowns even amid strong underlying performance.

Rarely I see high-growth, value plays in the market. I think Hims & Hers Health is such a rare case: a world-class, high-growth company still being valued as a risky startup. A DCF model based on 2030 guidance suggests a $64 fair value per share, with potential to far exceed that price due to management's conservative guidance. I think HIMS stock's fair value is above $84 per share, with potent...

Hims' operating leverage was outstanding at 5:1 over revenue growth. This is irrefutable proof of a scalable business. Hims' new TAMs should provide billions to the top line, hundreds of millions to the bottom, and dollars to EPS. Hims is likely a decade-plus ahead of competitors at this point with 'The Hims Trinity.'